Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $178.2 million versus the consensus estimate of $163.97 million.

GUIDANCE:

Repligen sees FY2021 EPS of $2.86-$2.91, versus the consensus of $2.68. Repligen sees FY2021 revenue of $655-665 million, versus the consensus of $640.6 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.